Remdesivir Shows Promise in Largest of Several Clinical Trials
Remdesivir Shows Promise in Largest of Several Clinical Trials
Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.
Remdesivir Shows Promise in Largest of Several Clinical Trials
Remdesivir Shows Promise in Largest of Several Clinical Trials

Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.

Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.

therapy
Blood Pressure Meds Point the Way to Possible COVID-19 Treatment
Blood Pressure Meds Point the Way to Possible COVID-19 Treatment
Ashley Yeager | Apr 2, 2020
There is little evidence that antihypertensive drugs worsen COVID-19, and scientists are instead exploring the idea that such medications—or their downstream effects—may actually alleviate symptoms.
More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes
Catherine Offord | Jan 15, 2019
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
US Companies Launch CRISPR Clinical Trial
US Companies Launch CRISPR Clinical Trial
Catherine Offord | Sep 3, 2018
The Germany-based study will test an ex vivo genome-editing therapy for the inherited blood disorder β-thalassemia.
Resurrecting Smells
Resurrecting Smells
The Scientist Staff | Oct 31, 2016
Visit the Monell Chemical Senses Center in Philadelphia, where researchers are striving to find a cure for anosmia, the loss of a sense of smell.
Cognitive Neuroscience Lurking in Art
Cognitive Neuroscience Lurking in Art
Kerry Grens | Oct 19, 2015
What can neuroscientists learn from the masters and other artists?